Sorrento Therapeutics, Inc.
SRNE
$0.0009
-$0.0001-10.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 56.52% | -242.07% | -54.89% | 25.23% | -31.30% |
| Total Depreciation and Amortization | 11.03% | 9.85% | 17.28% | -5.33% | 3.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.13% | 222.88% | 78.27% | -99.71% | 45.90% |
| Change in Net Operating Assets | 485.81% | 761.67% | 406.98% | 260.71% | 271.37% |
| Cash from Operations | 31.28% | 40.67% | 5.27% | 26.40% | -3.15% |
| Capital Expenditure | 94.82% | 96.68% | -104.80% | -226.38% | 22.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -77.47% | 80.97% | 107.51% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 75.99% | -- | -- |
| Cash from Investing | 91.90% | 112.32% | -128.30% | -249.96% | -102.20% |
| Total Debt Issued | 272,264.29% | -26.85% | -93.97% | 229.18% | -100.26% |
| Total Debt Repaid | 97.26% | 92.64% | -174.45% | -163.39% | -127.04% |
| Issuance of Common Stock | -- | -86.04% | -9.32% | 65.46% | 101.08% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 112.62% | -64.70% | -64.60% | 78.48% | 19.15% |
| Foreign Exchange rate Adjustments | -49.35% | 154.35% | 198.80% | -1,994.00% | -250.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 177.22% | -81.37% | -1,432.64% | 100.91% | -216.70% |